Marker Therapeutics Inc (MRKR)

$1.40 +0.18 (14.34%)
Market Cap 21.51M
Revenue (ttm) 3.55M
Net Income (ttm) -12.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -342.54%
Debt to Equity Ratio 0.00
Volume 69,754
Avg Vol 60,556
Day's Range N/A - N/A
Shares Out 16.67M
Stochastic %K 49%
Beta 1.50
Analysts Strong Sell
Price Target $7.87

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, United States
dwaslimit1
dwaslimit1 Aug. 21 at 5:06 PM
$MRKR you mean it took Moderna issuing a press release on the promise of vaccines in cancer trials to realize that Marker should be worth 100 times where it's at today? Get in on the ground floor! They have a decade of data to back up their efficacy.
0 · Reply
Bullish_Wicks
Bullish_Wicks Aug. 20 at 3:42 AM
$MRKR $GLMD Best ticker heading into tomorrow PWCM! This Crypto play is setting up for a monster move, insanely small float and fits the theme! Make sure to put PWCM on ur watch bulls!!!
0 · Reply
TerribleExample563
TerribleExample563 Aug. 19 at 7:36 PM
$MRKR what is going on here? Never seen this move
1 · Reply
dwaslimit1
dwaslimit1 Aug. 19 at 5:00 PM
$MRKR their product is superior to Moderna considering it doesn't have to be personalized. It's much more versatile. They've also had compelling efficacy without being a conjunction therapy which is also why it is superior to Moderna. I don't see why this can't go to 100 million.
0 · Reply
MrDint
MrDint Aug. 19 at 3:06 PM
$MRKR are they making love again? Did Vera whisper to HC Wainwright that its coming so they running it up? u really can't put anything pass these fckers
0 · Reply
itsMeRich
itsMeRich Aug. 19 at 3:03 PM
$MRKR moving up with the rest of the vaccine stocks…… doubt it lasts
1 · Reply
GoIrish1776
GoIrish1776 Aug. 19 at 12:08 PM
Personalized cancer vaccine from Moderna, Merck shows promise in late-stage trial $MRKR https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
2 · Reply
MrDint
MrDint Aug. 18 at 1:17 PM
$MRKR they received 4 million from Department of War in July and did not issue a press release!?!? Yet the stock climb to 1.70s in July. So retailers are left in the dark but the insiders and Wall Street are making love. What a terrible company.
0 · Reply
itsMeRich
itsMeRich Aug. 16 at 1:18 PM
$MRKR Marker’s management absolutely sucks! No updates to their shareholders on their trials-no press releases- absolutely ridiculous! Why would anyone invest in this company?
0 · Reply
JohnStuartMill
JohnStuartMill Aug. 15 at 6:32 AM
$MRKR Management noted existing cash resources project runway only into the second quarter of 2027, "creating substantial doubt about the company’s ability to continue as a going concern without additional funding." "We have no sources of income, other than grant income, to provide incoming cash flows to sustain our future operations" GREAT, I'd much rather hear ... "creating substantial doubt about the company’s ability to continue as a going concern", than updates on Lymphoma or new patients or Pancreatic.
0 · Reply
Latest News on MRKR
Marker Therapeutics Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 7 days ago

Marker Therapeutics Quarterly report: Q2 2026

Marker Therapeutics Quarterly report: Q1 2026

May 18, 2026, 2:00 AM EDT - 3 months ago

Marker Therapeutics Quarterly report: Q1 2026

Marker Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Marker Therapeutics Proxy statement: Proxy filing

Marker Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Marker Therapeutics Proxy statement: Proxy filing

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

2026-03-18T21:35:16.000Z - 5 months ago

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Mar 18, 2026, 5:31 PM EDT - 5 months ago

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Marker Therapeutics Earnings release: Q4 2025

Marker Therapeutics Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Marker Therapeutics Annual report: Q4 2025

Marker Therapeutics Proxy statement: Proxy Filing

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 6 months ago

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Marker announces Baylor’s TACTOPS study featured on Good Morning America

2026-01-26T12:15:08.000Z - 7 months ago

Marker announces Baylor’s TACTOPS study featured on Good Morning America

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

2026-01-05T12:25:31.000Z - 8 months ago

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Jan 5, 2026, 7:00 AM EST - 8 months ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-08T13:30:08.000Z - 9 months ago

Marker Therapeutics initiated with a Buy at H.C. Wainwright

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

2025-11-14T12:05:51.000Z - 10 months ago

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics Earnings release: Q3 2025

Marker Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics Quarterly report: Q3 2025

Marker Therapeutics appoints Penkus Corzo to board of directors

2025-11-05T12:50:27.000Z - 10 months ago

Marker Therapeutics appoints Penkus Corzo to board of directors

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 5, 2025, 7:30 AM EST - 10 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Nov 3, 2025, 9:15 AM EST - 10 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics announces first patient treated in off-the-shelf program

2025-10-06T11:40:46.000Z - 11 months ago

Marker Therapeutics announces first patient treated in off-the-shelf program

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Oct 6, 2025, 7:30 AM EDT - 11 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:30 PM EDT - 1 year ago

Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Transcript: Study Update

Aug 26, 2025, 8:30 AM EDT - 1 year ago

Marker Therapeutics Transcript: Study Update

Marker Therapeutics Press release: Study Update

Aug 26, 2025, 8:30 AM EDT - 1 year ago

Marker Therapeutics Press release: Study Update

Marker Therapeutics Slides: Corporate Presentation

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Corporate Presentation

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

2025-08-26T11:11:07.000Z - 1 year ago

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Quarterly report: Q2 2025

Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 12:30 PM EDT - 1 year ago

Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

2025-06-17T12:11:26.000Z - 1 year ago

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Slides: Corporate Presentation

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Corporate Presentation

Marker Therapeutics reports evidence from Phase 1 APOLLO study

2025-05-20T12:15:28.000Z - 1 year ago

Marker Therapeutics reports evidence from Phase 1 APOLLO study

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics Slides: Investor Presentation

May 20, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Investor Presentation

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Marker Therapeutics Quarterly report: Q1 2025

Marker Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

2025-03-31T12:50:08.000Z - 1 year ago

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Annual report: Q4 2024

Marker Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Earnings release: Q4 2024

Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T11:32:28.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T10:17:01.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics initiated with a Buy at Brookline

2025-02-10T23:05:05.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Brookline

Marker Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics files to sell 10.06M shares of common stock for holders

2025-01-10T22:15:17.000Z - 1 year ago

Marker Therapeutics files to sell 10.06M shares of common stock for holders

Marker Therapeutics Registration statement: Registration Filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Registration statement: Registration Filing

Biotech Alert: Searches spiking for these stocks today

2024-12-20T15:50:26.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ARDX MRK NVO OGI UTHR VKTX

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

2024-12-19T13:25:36.000Z - 1 year ago

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

Marker Therapeutics provides update on MT-601 patients

2024-12-19T13:10:51.000Z - 1 year ago

Marker Therapeutics provides update on MT-601 patients

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Slides: Corporate Presentation

Dec 19, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Slides: Corporate Presentation

Marker Therapeutics awarded $9.5M grant from CPRIT

2024-12-17T12:05:36.000Z - 1 year ago

Marker Therapeutics awarded $9.5M grant from CPRIT

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics files $300M mixed securities shelf

2024-11-27T21:30:12.000Z - 1 year ago

Marker Therapeutics files $300M mixed securities shelf

Marker Therapeutics Registration statement: Registration Filing

Nov 27, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Registration statement: Registration Filing

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Quarterly report: Q3 2024

Marker Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Earnings release: Q3 2024

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q2 2024

Marker Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q2 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 2 years ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q1 2024

Marker Therapeutics Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q1 2024

Marker Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Proxy statement: Proxy Filing

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics Annual report: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Annual report: Q4 2023

Marker Therapeutics Earnings release: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q4 2023

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 3 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Marker Therapeutics Quarterly report: Q3 2023

Marker Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Marker Therapeutics Earnings release: Q3 2023

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 3 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Quarterly report: Q2 2023

Marker Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q2 2023

Marker Therapeutics Transcript: Status Update

Aug 9, 2023, 11:00 AM EDT - 3 years ago

Marker Therapeutics Transcript: Status Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 3 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Proxy statement: Proxy Filing

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics Annual report: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Annual report: Q4 2022

Marker Therapeutics Earnings release: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q4 2022

Marker Therapeutics Registration statement: Registration Filing

Dec 23, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics Registration statement: Registration Filing

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 4 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

Marker Therapeutics Quarterly report: Q3 2022

Marker Therapeutics Earnings release: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

Marker Therapeutics Earnings release: Q3 2022

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 4 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q2 2022

Marker Therapeutics Earnings release: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q2 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 4 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Marker Therapeutics Quarterly report: Q1 2022

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q1 2022

Marker Therapeutics Earnings release: Q1 2022

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q1 2022

dwaslimit1
dwaslimit1 Aug. 21 at 5:06 PM
$MRKR you mean it took Moderna issuing a press release on the promise of vaccines in cancer trials to realize that Marker should be worth 100 times where it's at today? Get in on the ground floor! They have a decade of data to back up their efficacy.
0 · Reply
Bullish_Wicks
Bullish_Wicks Aug. 20 at 3:42 AM
$MRKR $GLMD Best ticker heading into tomorrow PWCM! This Crypto play is setting up for a monster move, insanely small float and fits the theme! Make sure to put PWCM on ur watch bulls!!!
0 · Reply
TerribleExample563
TerribleExample563 Aug. 19 at 7:36 PM
$MRKR what is going on here? Never seen this move
1 · Reply
dwaslimit1
dwaslimit1 Aug. 19 at 5:00 PM
$MRKR their product is superior to Moderna considering it doesn't have to be personalized. It's much more versatile. They've also had compelling efficacy without being a conjunction therapy which is also why it is superior to Moderna. I don't see why this can't go to 100 million.
0 · Reply
MrDint
MrDint Aug. 19 at 3:06 PM
$MRKR are they making love again? Did Vera whisper to HC Wainwright that its coming so they running it up? u really can't put anything pass these fckers
0 · Reply
itsMeRich
itsMeRich Aug. 19 at 3:03 PM
$MRKR moving up with the rest of the vaccine stocks…… doubt it lasts
1 · Reply
GoIrish1776
GoIrish1776 Aug. 19 at 12:08 PM
Personalized cancer vaccine from Moderna, Merck shows promise in late-stage trial $MRKR https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
2 · Reply
MrDint
MrDint Aug. 18 at 1:17 PM
$MRKR they received 4 million from Department of War in July and did not issue a press release!?!? Yet the stock climb to 1.70s in July. So retailers are left in the dark but the insiders and Wall Street are making love. What a terrible company.
0 · Reply
itsMeRich
itsMeRich Aug. 16 at 1:18 PM
$MRKR Marker’s management absolutely sucks! No updates to their shareholders on their trials-no press releases- absolutely ridiculous! Why would anyone invest in this company?
0 · Reply
JohnStuartMill
JohnStuartMill Aug. 15 at 6:32 AM
$MRKR Management noted existing cash resources project runway only into the second quarter of 2027, "creating substantial doubt about the company’s ability to continue as a going concern without additional funding." "We have no sources of income, other than grant income, to provide incoming cash flows to sustain our future operations" GREAT, I'd much rather hear ... "creating substantial doubt about the company’s ability to continue as a going concern", than updates on Lymphoma or new patients or Pancreatic.
0 · Reply
Trak2
Trak2 Aug. 14 at 11:16 PM
$MRKR 10-q is out
0 · Reply
MrDint
MrDint Aug. 12 at 7:27 PM
$MRKR Fake bump. Being done in anticipation of earnings report. Current projected cash on hand is somewhere around 12 million and with no new data, post earnings report it will slide to 80 cents. Only a meaningful pr can change that trajectory but Vera is not your guy. He is a prop not a real CEO
0 · Reply
MrDint
MrDint Aug. 11 at 4:20 PM
$MRKR chart is showing 80 cents again. every move upwards has being rejected so far: couldn't break 1.80 on the run up some weeks back, and couldnt break 1.35 after the collapse to 1.05 All signs point further south.
0 · Reply
MrDint
MrDint Aug. 7 at 7:35 PM
$MRKR offering... whispering is they short on cash and intend to do a raise. chart shows 50 cents is possible with a bottom of .22 cents. historic lows. how Vera still has his job?
0 · Reply
tradingviewcyp
tradingviewcyp Aug. 5 at 7:36 PM
$MRKR Somebody is playing with this stock by using their $70K capital. Up down up down. And Dr. Vera doesn’t care. His company is in stock market, when he needs money, he announces same news to the media to get money from fools. This is the game. Everybody can use his company for getting easy money from customers, he doesn’t care. You can check this on buy/sells.
0 · Reply
tradingviewcyp
tradingviewcyp Aug. 5 at 3:52 PM
$MRKR Hehehehe way to below 1$. ✌️
0 · Reply
MrDint
MrDint Aug. 3 at 6:54 PM
$MRKR is the move up based upon a retailer emailing the company the response is a promise of robust data soon? how soon and how robust? Vera is not the guy to bet on. Truckloads of promises only.
0 · Reply
itsMeRich
itsMeRich Aug. 3 at 3:13 PM
$MRKR up 15%….. but on low volume….. wonder if we can expect to hear some news form this silent management team.
1 · Reply
contrast82
contrast82 Aug. 3 at 1:42 PM
$MRKR 🤔😋
0 · Reply
itsMeRich
itsMeRich Aug. 3 at 1:41 PM
$MRKR 🤔
0 · Reply
MrDint
MrDint Aug. 3 at 1:28 AM
$MRKR If Marker had the goods, BMS can pay just a fraction for a great pipeline. But Vera sucks, and like a car salesman is all promises and little to nothing to show. They can't even sell the company for a 100 million let alone anything beyond. AstraZeneca in talks with Bristol Myers Squibb on $400B megadeal, FT reports https://www.cnbc.com/2026/08/02/astrazeneca-and-bristol-myers-squibb-mull-400-billion-deal-report-.html?__source=androidappshare
0 · Reply
tradingviewcyp
tradingviewcyp Jul. 30 at 11:38 AM
$MRKR rubbish, rubbish, rubbish. Way to under 1. They don’t care shareholders. Dr Vera and members of board don’t know anything about stock market. I asked the results of the project and they didn’t reply. They will never reply. The sceranio is that; they will announce stupid news on the newspapers about project. 66% percent accuracy bla bla. They will try to hunt new buyers. Don’t believe them, there isn’t any good news.
0 · Reply